This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-22. Anything still debated is marked as such rather than presented as settled.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
==== MeSH E05.337.550 – drug evaluation, preclinical ==== MeSH E05.337.550.200 – drug screening assays, antitumor MeSH E05.337.550.200.800 – tumor stem cell assay MeSH E05.337.550.200.900 – xenograft model antitumor assays MeSH E05.337.550.200.900.830 – subrenal capsule assay MeSH E05.337.550.400 – microbial sensitivity tests MeSH E05.337.550.400.800 – serum bactericidal test MeSH E05.337.550.600 – parasitic sensitivity tests
treatment of serious infections caused by susceptible organisms resistant to penicillins, such as methicillin-resistant S. aureus (MRSA) and multidrug-resistant S. epidermidis (MRSE), treatment of infections in individuals with serious allergy to penicillins, treatment of pseudomembranous colitis caused by C. difficile; in particular, in cases of relapse or where the infection is unresponsive to metronidazole treatment (for this indication, vancomycin is given orally rather than intravenously), treatment of infections caused by Gram-positive microorganisms in patients with serious allergies to beta-lactam antimicrobials, antibacterial prophylaxis for endocarditis after certain procedures in penicillin-hypersensitive people at high risk, surgical prophylaxis for major procedures involving implantation of prostheses in institutions with a high rate of MRSA or MRSE, early in treatment as an empiric antibiotic for possible MRSA infection while waiting for culture identification of the infecting organism, halting the progression of primary sclerosing cholangitis and preventing symptoms; vancomycin does not cure the patient and success is limited, treatment of endophthalmitis by intravitreal injection for Gram-positive bacteria coverage; it has been used to prevent the condition but is not recommended due to the risk of side effects.
==== Methadone clinics ==== In the United States, prescription of methadone requires intensive monitoring and must be obtained in-person from an Opioid Treatment Program—colloquially known as a 'methadone clinic'—when prescribed for opioid use disorder (OUD). According to federal laws, methadone cannot be prescribed by a doctor and obtained from a pharmacy to treat addiction. Because of its long half-life, methadone is almost invariably prescribed to be taken in a single daily dose. At nearly all methadone clinics in the US, patients must visit a clinic to receive and take their dose under the supervision of a nurse. Patients earn take home bottles with their daily dose, by providing clean drug tests and doing therapy. These bottles will be taken away if they provide a dirty drug test, or break clinic rules. They can be earned back. Both patients who are new to methadone treatment and high-risk patients—such as those who are using drugs and alcohol, including cannabis in some states—must visit the clinic daily.
== Research == (2R,6R)-HNK is under development by the National Institute of Mental Health (NIMH) in the United States for the treatment of depression. As of late 2019, it is in phase I clinical trials for this indication. It is also under development under the developmental code name SPL-801-B by Cybin for depressive disorders.
=== COVID 19 === The COVID 19 pandemic marked a new chapter in Hetero’s public health contributions. In March 2020, as the pandemic took hold, Hetero donated INR 10 crore to the Telangana government’s COVID relief fund, composed of 5 crores in direct funding and 5 crores in essential medicines including Hydroxychloroquine Sulphate, Lopinavir/Ritonavir and Oseltamivir. During this period, Hetero also began supplying medicines to countries such as the United States, Italy, Spain, Israel, and Algeria. In May 2020, Hetero entered a licensing agreement with Gilead Sciences to manufacture and distribute a generic version of Remdesivir in 127 countries. The Drug Controller General of India granted manufacturing and marketing approval on 21 June 2020, making Covifor the first generic Remdesivir approved in India. An initial consignment of 20000 Vials was distributed within India across major cities including Hyderabad, Delhi, Mumbai, Kolkata and Chennai, priced at ₹5400 per vial. By August 2020, Hetero had supplied approximately 800000 doses of Remdesivir in India alone, treating more than 100000 patients. In the same month, Hetero received authorization from the South African Health Products Regulatory Authority (SAHPRA) to import 'Remdesivir' in South Africa for the treatment for Covid-19, and committed to supplying 60000 vials a month. In July 2020, Hetero received approval from the DCGI to manufacture and market a generic version of Favipiravir tablets under the name Favivir, which is used to treat patients with mild to moderate COVID-19 symptoms.
Sources: en.wikipedia.org
==== Distribution ==== Trazodone is not sequestered into any tissue. The medication is 89 to 95% protein-bound. The volume of distribution of trazodone is 0.8 to 1.5 L/kg. Trazodone is highly lipophilic.
=== Venezuela === On 18 August 2025, Maduro said the US "has gone mad and has renewed its threats to Venezuela's peace and tranquility" and "announced the planned deployment of more than 4.5 million militia members" around Venezuela. The Economist was skeptical of the announcement, stating, "Election receipts show he received fewer than 3.8m votes last year; it is improbable that more people would fight to defend him than would vote for him." The International Institute for Strategic Studies estimated the militia had 343,000 members as of 2020. The BBC reported that many of the recently mobilized militia are "mostly made up of volunteers from poor communities, although public sector workers have reported being pressured into joining them as well." On 25 August, Maduro "said 15,000 'well armed and trained' men had been deployed to states near the Colombian border," per The Economist.
=== One-Pot Synthesis === One-pot reactions involve combining all reactants simultaneously under appropriate conditions. This straightforward approach has proven successful for many simpler cage structures, particularly those formed through imine condensation. The success of one-pot synthesis often depends on the reversible nature of bond formation, allowing the system to self-correct and converge on the thermodynamically favored product. The reaction conditions, such as temperature, solvent choice, and concentration, play crucial roles in determining the outcome. For example, in imine cage synthesis, polar aprotic solvents like dichloromethane or chloroform are often preferred as they facilitate imine formation while allowing the removal of water byproduct. Additionally, techniques such as slow addition of components or temperature control can be employed to enhance selectivity towards the desired cage product.
{\displaystyle {\frac {d}{dt}}{\begin{pmatrix}n_{E}\\n_{I}\end{pmatrix}}={\begin{pmatrix}-1/\tau _{E}&R_{0}/\tau _{I}\\1/\tau _{E}&-1/\tau _{I}\end{pmatrix}}{\begin{pmatrix}n_{E}\\n_{I}\end{pmatrix}}.}
Sources: en.wikipedia.org
== Optimizing protein purification == Combinations of chromatographic methods can be used to purify a target molecule. The purpose of purifying proteins with FPLC is to deliver quantities of the target at sufficient purity in a biologically active state to suit its further use. The quality of the end product varies depending the type and amount of starting material, efficiency of separation, and selectivity of the purification resin. The ultimate goal of a given purification protocol is to deliver the required yield and purity of the target molecule in the quickest, cheapest, and safest way for acceptable results. The range of purity required can be from that required for basic analysis (SDS-PAGE or ELISA, for example), with only bulk impurities removed, to pure enough for structural analysis (NMR or X-ray crystallography), approaching >99% target molecule. Purity required can also mean pure enough that the biological activity of the target is retained. These demands can be used to determine the amount of starting material required to reach the experimental goal. If the starting material is limited and full optimization of purification protocol cannot be performed, then a safe standard protocol that requires a minimum adjustment and optimization steps are expected. This may not be optimal with respect to experimental time, yield, and economy but it will achieve the experimental goal.
In 1946, the Atomic Bomb Casualty Commission (ABCC) was established by the National Research Council of the National Academy of Sciences by order of U.S. President Harry S. Truman to study the long-term effects of radiation on survivors of the atomic bombings. In 1975, the ABCC was replaced by the Radiation Effects Research Foundation (RERF). Organizations such as the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), founded in 1955, and the National Academy of Sciences - Advisory Committee on the Biological Effects of Ionizing Radiation (BEIR Committee), founded in 1972, analyze the effects of radiation exposure on humans on the basis of atomic bomb victims who have been examined and, in some cases, medically monitored for decades. They determine the course of the mortality rate as a function of the age of the radiation victims in comparison with the spontaneous rate, and also the dose-dependency of the number of additional deaths. To date, 26 UNSCEAR reports have been published and are available online, most recently in 2017 on the effects of the Fukushima nuclear accident. By 1949, Americans felt increasingly threatened by the possibility of nuclear war with the Soviet Union and sought ways to survive a nuclear attack. The U.S. Federal Civil Defense Administration (USFCDA) was created by the government to educate the public on how to prepare for such an attack. In 1951, with the help of this agency, a children's educational film was produced in the U.S.
Undecaprenyl phosphate will attack the UDP-MurNAc penta, creating a PP-MurNac penta, which is now a lipid (lipid I). EC 2.7.8.13 by MraY. UDP-GlcNAc is then transported to MurNAc, creating Lipid-PP-MurNAc penta-GlcNAc (lipid II), a disaccharide, also a precursor to peptidoglycan. EC 2.4.1.227 by MurG. Lipid II is transported across the membrane by flippase (MurJ), a discovery made in 2014 after decades of searching. Once it is there, it is added to the growing glycan chain by the enzyme peptidoglycan glycosyltransferase (GTase, EC 2.4.1.129). This reaction is known as transglycosylation. In the reaction, the hydroxyl group of the GlcNAc will attach to the MurNAc in the glycan, which will displace the lipid-PP from the glycan chain. In a final step, the DD-transpeptidase (TPase, EC 3.4.16.4) crosslinks individual glycan chains. This protein is also known as the penicillin-binding protein. Some versions of the enzyme also performs the glycosyltransferase function, while others leave the job to a separate enzyme.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.